The level of reverse transcriptase (RT) in human immunodeficiency virus type 1 particles affects susceptibility to nonnucleoside RT inhibitors but not to lamivudine.
We investigated the relationship between the level of reverse transcriptase (RT) in human immunodeficiency virus type 1 (HIV-1) particles and susceptibility to nonnucleoside reverse transcriptase inhibitors (NNRTIs). HIV-1 virions containing different active levels of RT were generated. Susceptibility to the NNRTIs efavirenz and nevirapine was inversely proportional to the level of enzymatically active RT. However, the sensitivity of HIV-1 to the nucleoside analog 3TC was not affected by the level of RT per particle. These data indicate that the susceptibility of HIV-1 to NNRTIs is influenced by RT activity.
HIV Drug Resistance Program, National Cancer Institute, Frederick, MD 21702, USA.
Zandrea
Z
Ambrose
John G
JG
Julias
Paul L
PL
Boyer
Vineet N
VN
Kewalramani
Stephen H
SH
Hughes
D019380:Anti-HIV Agents / Q000494:pharmacology*; D054303:HIV Reverse Transcriptase / Q000032:analysis*; D015497:HIV-1 / Q000187:drug effects* / Q000201:enzymology*; D019259:Lamivudine / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology*
D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D054303:HIV Reverse Transcriptase